As low ASS1 and OTC expressions were shown to facilitate the response to the combination treatment, we then investigated the clinical relevance of this therapeutic approach by analyzing our in-house patient cohort with pancreatic cancer. This evidence concerns the gene OTC and familial pancreatic carcinoma.